TY - JOUR
T1 - Management of primary hepatic malignancies during the COVID-19 pandemic
T2 - recommendations for risk mitigation from a multidisciplinary perspective
AU - Barry, Aisling
AU - Apisarnthanarax, Smith
AU - O'Kane, Grainne M.
AU - Sapisochin, Gonzalo
AU - Beecroft, Robert
AU - Salem, Riad
AU - Yoon, Sang Min
AU - Lim, Young Suk
AU - Bridgewater, John
AU - Davidson, Brian
AU - Scorsetti, Marta
AU - Solbiati, Luigi
AU - Diehl, Adam
AU - Schuffenegger, Pablo Munoz
AU - Sham, Jonathan G.
AU - Cavallucci, David
AU - Galvin, Zita
AU - Dawson, Laura A.
AU - Hawkins, Maria A.
N1 - Funding Information:
RS is a consultant for Boston Scientific, Cook, Sirtex, Eisai, Genentech, and Becton Dickinson. PMS is on the Advanced Radiotherapy Committee for the International Association for the Study of Lung Cancer. LAD has a licensing agreement with Raysearch for image registration software in a system for radiation treatment planning. GMK is a consultant for Eisai. GS declares research funding from Roche and Bayer, outside the submitted work. AD declares funding from the Clinical Research Division at Fred Hutchinson Cancer Research Center, outside the submitted work. MAH and JB declare funding from the NIHR Biomedical Research Centre at University College London Hospitals National Health Service Foundation Trust, outside the submitted work. All other authors declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/8
Y1 - 2020/8
N2 - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.
AB - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85086645374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086645374&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(20)30182-5
DO - 10.1016/S2468-1253(20)30182-5
M3 - Review article
C2 - 32511951
AN - SCOPUS:85086645374
SN - 2468-1253
VL - 5
SP - 765
EP - 775
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 8
ER -
